XTL Biopharmaceuticals Ltd ADR Total Liabilities
XTL Biopharmaceuticals Ltd ADR total liabilities. Based on the latest financial reports, XTL Biopharmaceuticals Ltd ADR (XTLB) has total liabilities worth $420.00K USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check XTLB asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of XTL Biopharmaceuticals Ltd ADR (2002–2025)
Total liabilities of XTL Biopharmaceuticals Ltd ADR from 2002 to 2025. This chart illustrates how XTL Biopharmaceuticals Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. Explore XTL Biopharmaceuticals Ltd ADR long-term investment allocation to see how much of total assets are deployed in long-term investments.
XTL Biopharmaceuticals Ltd ADR Competitors by Total Liabilities
The table below lists competitors of XTL Biopharmaceuticals Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bermas SA
RO:BRM
|
Romania | RON15.28 Million |
|
Reliance Chemotex Industries Limited
NSE:RELCHEMQ
|
India | Rs-1.43 Billion |
|
CS Corporation
KQ:065770
|
Korea | ₩2.63 Billion |
|
Equus Total Return Closed Fund
NYSE:EQS
|
USA | $5.74 Million |
|
NEXE Innovations Inc
V:NEXE
|
Canada | CA$2.85 Million |
|
Niobay Metals Inc
V:NBY
|
Canada | CA$187.11K |
|
João Fortes Engenharia S.A.
SA:JFEN3
|
Brazil | R$1.02 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down XTL Biopharmaceuticals Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see XTL Biopharmaceuticals Ltd ADR balance sheet assets.
Liquidity & Leverage Metrics
XTL Biopharmaceuticals Ltd ADR Total Liabilities Ratios Explained
XTL Biopharmaceuticals Ltd ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how XTL Biopharmaceuticals Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for XTL Biopharmaceuticals Ltd ADR (2002–2025)
The table below shows the annual total liabilities of XTL Biopharmaceuticals Ltd ADR from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $420.00K | -86.52% |
| 2024-12-31 | $3.12 Million | +1412.14% |
| 2023-12-31 | $206.00K | +10.16% |
| 2022-12-31 | $187.00K | -85.45% |
| 2021-12-31 | $1.28 Million | +405.91% |
| 2020-12-31 | $254.00K | +9.48% |
| 2019-12-31 | $232.00K | -8.30% |
| 2018-12-31 | $253.00K | -91.47% |
| 2017-12-31 | $2.97 Million | +799.09% |
| 2016-12-31 | $330.00K | -24.31% |
| 2015-12-31 | $436.00K | -54.82% |
| 2014-12-31 | $965.00K | -21.54% |
| 2013-12-31 | $1.23 Million | -25.99% |
| 2012-12-31 | $1.66 Million | +164.23% |
| 2011-12-31 | $629.00K | -34.68% |
| 2010-12-31 | $963.00K | +36.02% |
| 2009-12-31 | $708.00K | -64.67% |
| 2008-12-31 | $2.00 Million | -63.98% |
| 2007-12-31 | $5.56 Million | +34.37% |
| 2006-12-31 | $4.14 Million | +6.18% |
| 2005-12-31 | $3.90 Million | -35.25% |
| 2004-12-31 | $6.02 Million | +41.86% |
| 2003-12-31 | $4.25 Million | +18.15% |
| 2002-12-31 | $3.59 Million | -- |
About XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more